Sjögren's disease & overlap diseases
Pilocarpine treatment of Sjögren's syndrome curative effect of meta-analysis of randomised controlled trials
Authors' conclusion
Based on the current evidence, oral pilocarpine does not significantly improve Schirmer's test results or breakup time with fluorescein BUT in patients with SS. However, it does enhance outcomes in the Whole Saliva Test, Bijsterveld's score, and fluorescein 1% staining.
Study context
- Population
- Patients with Sjögren's syndrome (SS)
- Participants
- 383 patients8 randomised controlled trials (RCTs)
- Comparison
- Oral pilocarpine vs control
- Outcome
- Efficacy of oral pilocarpine in SS: tear, ocular surface and saliva measures
Pooled result
As reported in the abstract
RR
- Schirmer's test, right eye; heterogeneity I2=97%; not significant
- 1.25 (95 % CI −0.68 to 3.18)
- Schirmer's test, left eye; heterogeneity I2=97%; not significant
- 5.15 (95% CI −1.73 to 12.02)
- Right breakup time with fluorescein; heterogeneity I2=89%; not significant
- 1.91 (95% CI −0.46 to 4.27)
- Left breakup time with fluorescein; heterogeneity I2=87%; not significant
- 1.74 (95% CI −0.29 to 3.77)
- Whole saliva test: significant improvement (RR, 95%CI, heterogeneity I2=90%)
- RR 0.20, 95%CI 0.09 to 0.30
- Bijsterveld's score, left eye: significant improvement (I²=90%)
- RR −4.18, 95%CI −7.14 to −1.21
- Bijsterveld's score, right eye: significant improvement (I²=92%)
- RR −4.11, 95%CI −7.37 to −0.85
- Fluorescein 1% staining, left eye: significant improvement (I²=0%)
- RR −0.81, 95%CI −1.26 to −0.36
- Fluorescein 1% staining, right eye: significant improvement (I²=0%)
- RR −0.74, 95%CI −1.19 to −0.28
Original publication
Pilocarpine treatment of Sjögren's syndrome curative effect of meta-analysis of randomised controlled trials. Clin Exp Rheumatol. Published 23 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →